The latest addition to the Biopharmaceutical Corporation’s development pipeline seems poised to allow Prometic access to a rapidly growing US$1.1bn market expected to nearly treble to over US$3bn over the next 5 years. Prometic last week announced that it had selected C1 Esterase Inhibitor (C1-INH) as its next plasma-derived drug candidate to be developed. The C1-INH protein is most commonly used for the treatment of hereditary angioedema (“HAE”), a rare genetic disorder in
15 May 2015
Prometic targets $3bn HAE market
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Prometic targets $3bn HAE market
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
15 May 2015 -
Author:
Derren Nathan -
Pages:
7
The latest addition to the Biopharmaceutical Corporation’s development pipeline seems poised to allow Prometic access to a rapidly growing US$1.1bn market expected to nearly treble to over US$3bn over the next 5 years. Prometic last week announced that it had selected C1 Esterase Inhibitor (C1-INH) as its next plasma-derived drug candidate to be developed. The C1-INH protein is most commonly used for the treatment of hereditary angioedema (“HAE”), a rare genetic disorder in